SEC Tracker
Get the app

Acura Pharmaceuticals

Acura Pharmaceuticals: signs a material agreement, completes an acquisition or sale of assets and takes on a new financial obligation

Form
8-K
Filed
Period
Importance
Major
Document
8-K
Exhibit 99.1
Press release
  • Signs a material agreement (1.01)
  • Completes an acquisition or sale of assets (2.01)
  • Takes on a new financial obligation (2.03)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Acura Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float not reported.

  1. Ayala Pharmaceuticals ADXS
  2. Ampio Pharmaceuticals AMPE
  3. Alterity Therapeutics ATHE
  4. Adhera Therapeutics ATRX
  5. Avricore Health AVCRF